ArticleNature nanotechnology2026
Amplifying tumour antigen presentations from intratumourally entrapped dendritic cells.
Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acoustoelectric nanoregulator for modulating the endoplasmic reticulum and mitochondria in cell fate regulation.Bioactive materials · 2027Article
- Advances in Research onInternational journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antigen presentation within solid tumours presents a significant clinical challenge for systemic immune activation. Although radiotherapy or chemotherapy can generate tumour antigens by destroying tumour cells, the insufficient number and impaired function of dendritic cells within solid tumours compromises effective antigen presentation. Here we present plant-derived nanoparticles coated with nanohydroxyapatite that promote dendritic cell activation and amplify the production of dendritic-cell-derived antigen-presenting vesicles in vivo through the modulation of intracellular immune conversion and calcium signalling. The technology, termed the intratumoural generation of immunopresentation vesicles after tumour exposure, enabled a dramatic enhancement in antigen presentation within lymph nodes and, consequently, boosted systemic immune response, exhibiting superior antitumour efficacy in multiple solid tumour models when combined with radiotherapy. This strategy of amplifying immunoreactive nanovesicle production in vivo may serve as a promising immunopotentiating platform, advancing various cancer treatments.
Indexed as
Identifiers
42315703What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.